Alpha Cognition Inc., a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, announced it has commenced a marketed public offering of units for up to $10 million. The offering will be conducted on a best efforts agency basis pursuant to the terms and conditions of an agency agreement to be entered into between the company and Raymond James Ltd. as sole bookrunner and lead agent on behalf of a syndicate of agents including, IA Private Wealth Inc., Echelon Wealth Partners and Leede Jones Gable Inc.

Read the full press release here: Alpha Cognition Announces Marketed Offering